Opie's Cardiovascular Drugs-9판

1: Drugs for Ischemic Heart Disease
Introduction
β-Blockers
Summary
Nitrates and Newer (or Nontraditional) Antianginals
Calcium Channel Blockers
Summary
Summary

2: Antihypertensive Therapies
Introduction
Drug Class Overview and Guidelines
Diuretics
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II Receptor Blockers
Mineralocorticoid Receptor Antagonists
β-Blockers
Central Sympatholytic Agents
α1-Adrenoreceptor Antagonists
Direct Vasodilators

3: Heart Failure
Introduction
Acute Decompensated Heart Failure
Pharmacotherapy
Vasodilators
Novel Vasodilators
Inotropes
β-Adrenergic Agonists
Phosphodiesterase Inhibitors
Calcium Sensitizers
Novel Inotropes
Vasopressors
Special Situations
Heart Failure Patients With Reduced Ejection Fraction
Pharmacotherapy
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Angiotensin Receptor Neprilysin Inhibitors
Mineralocorticoid-Receptor Antagonists
Sodium-Glucose Cotransporter-2 Inhibitors
Additional Therapy
Combination of Hydralazine Plus Isosorbide Dinitrate
If Channel Inhibitor
Digoxin
Iron Supplementation and Anemia
Fish Oil and Marine Omega-3 Polyunsaturated Fatty Acids
Micronutrient Supplementation
Oral Anticoagulants and Antiplatelet Therapy
Statins
Antiarrhythmic Agents
Direct Renin Inhibitors
Heart Failure Patients With Preserved Ejection Fraction
Heart Failure Patients With Mid-Range Ejection Fraction
Pharmacotherapy
Renin-Angiotensin Blockade: Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor
Blockers
Mineralocorticoid Receptor Antagonists
Angiotensin Receptor Neprilysin Inhibitors
β-Blockers
Digoxin, Calcium Channel Blockers, and Ivabradine
Nitric Oxide and cGMP Signaling: Phosphodiesterase-5 Inhibitors, Nitrates, and Soluble
Guanylate Cyclase Stimulators
Other Medications
Reverse Cardiac Remodeling: Remission Versus Recovery
Drugs That Should Be Avoided or Used Cautiously in Heart Failure
Pharmacological Treatment of Selected Cardiomyopathies
Future Perspectives
Summary

4: Drugs for Diabetes
Metabolic Syndrome and Prediabetes
Diabetes Prevention
Cardiovascular Disease Risk Assessment
Value of Improved Glycemic Control
Importance of Large Cardiovascular Disease Outcome Trials
Drugs That Lower Cardiovascular Disease Risk
Drugs That Do Not Lower Cardiovascular Disease Risk
Hypoglycemia
Guidelines
Future Directions

5: Drugs for Obesity
Drug Class Overview and Guidelines
Weight Loss Intervention
Pathophysiology and Mechanism of Action
Conclusion

6: Lipid-Modifying Drugs
Inflammation and Atherogenesis
Prevention and Risk Factors
Blood Lipid Profile
Lipids in Special Population Groups
Dietary and Other Nondrug Therapy for Dyslipidemia
Drug Therapy for Dyslipidemia
Summary

7: Drugs Targeting Inflammation
Basic Concepts of Inflammation Biology
Stimuli for the Inflammatory Response
Central Hubs of Inflammatory Signaling (see Fig. 7.2)
Mediators
Conclusions, Challenges, and Future Perspective

8: Antithrombotic Drugs
Introduction
Thrombosis
Emerging Construct and Future Targets for Antithrombotic Therapy
Cardiovascular Drug Therapy
Platelet-Directed Therapies
Platelet P2Y12 Receptor Antagonists
Periprocedural Management of Antiplatelet Therapy
Intravenous Platelet GPIIb/IIIa Receptor Antagonists
Summary of Recommendations in Patients With ACS
Anticoagulants
Parenteral Anticoagulant Drugs
Direct Thrombin Inhibitors
Direct FXa Inhibitors
Indirect, Selective FXa Inhibitors
Direct Thrombin Inhibitors
Argatroban
Reversal and Replacement Therapy for Parenteral Anticoagulants
Oral Anticoagulant Drugs
Pharmacokinetics and Drug Disposition
Oral Direct Thrombin Inhibitors
Vitamin K Antagonists
Reversal and Replacement of Direct Oral Anticoagulant Drugs
Achieving Good Hemostasis
Conclusions

9: Antiarrhythmic Drugs
Overview of New Developments
Antiarrhythmic Drugs
Inhaled Agents
New Developments in Antiarrhythmics
Antiarrhythmic Choice for Arrhythmias
Summary

10: Vascular Medicine Drugs
Overview

11: Drugs for Pulmonary Hypertension
Drug Class Overview and Guidelines
Mechanisms of Action
Differences Among Drugs in Class
Data for Use
Side Effects
Drug Interactions
Experimental Drugs
Conclusions